þ / þ receptor mice, the simultaneous injection of the Y 2 antagonist BIIE0246 with BIBO3304 abolished Y 2 agonist-induced decreases in blood flow over the dose range used (10 -100 pmol). When the Y 2 receptor antagonist BIIE0246 was given alone, it was not able to significantly affect the PYY(3 -36)-induced response, whereas the Y 1 receptor antagonist BIBO3304 partially (Po0.001) inhibited the decrease in blood flow evoked by PYY(3 -36) at the highest dose. 5 NPY did not mediate either oedema formation, even when investigated in the presence of the vasodilator calcitonin gene-related peptide (CGRP), or neutrophil accumulation in murine skin. 6 We conclude that the major vasoactive activity of NPY in the cutaneous microvasculature is to act in a potent manner to decrease blood flow via Y 1 receptors, with evidence for the additional involvement of postjunctional Y 2 receptors. Our results do not provide evidence for a potent proinflammatory activity of NPY in the cutaneous microvasculature.
Introduction
Neuropeptide Y (NPY) is a 36 amino-acid peptide that is widely distributed throughout the central and peripheral nervous systems. It is primarily located in perivascular sympathetic nerves that innervate blood vessels in tissues such as the skin (Weihe & Hartschuh, 1988; Kashiba et al., 1994) . Established as a potent vasoconstrictor neuropeptide Edvinsson et al., 1984a) , NPY is coreleased with noradrenaline (NA) at the sympathetic neuroeffector junction (Lundberg et al., 1985; Edvinsson et al., 1987) , and, therefore, can also potentiate the actions of NA (Ekblad et al., 1984; Edvinsson et al., 1984b) . NPY is structurally related to its hormonal homologues peptide YY (PYY) and pancreatic polypeptide (PP). Together, they influence a wide variety of physiological processes through a family of receptors already cloned and named Y 1 , Y 2 , Y 4 , Y 5 and y 6 according to their molecular and pharmacological activity (Michel et al., 1998) . NPY can act upon all Y receptors (with the exception of Y 4 receptors), while formed via the action of the dipeptidyl peptidase IV (Mentlein et al., 1993 ) is a Y 2 /Y 5 -preferring agonist. Similarly, full-length-circulating PYY can be converted to , the fragment preferentially activating Y 2 (Grandt et al., 1994) but also exhibiting affinity for Y 5 receptors (Michel et al., 1998) . Since the Y 5 receptor is preferentially expressed in the brain, NPY(3 -36) released from sympathetic peripheral nerves and circulating PYY(3 -36) are both assumed to be endogenous peripheral Y 2 agonists. There is evidence for the involvement of both Y 1 and Y 2 receptors in the cardiovascular system, although the precise mechanisms and relative importance is unclear (see Malmstro¨m, 2002) .
Y 1 and Y 2 receptors are members of the seven transmembrane G-protein-linked receptor families with approximately 30% primary sequence identity (Herzog et al., 1992; Gerald et al., 1995) . There is good evidence that the Y 1 receptor is present postjunctionally and mediates vasoconstriction in vivo (Fuhlendorff et al., 1990; Lundberg & Modin, 1995; Malmstro¨m & Lundberg, 1996; Nilsson et al., 1996) . In general, it was originally assumed that the Y 2 receptor was prejunctional and that its activation could inhibit either NPY or NA release, with evidence obtained from nonvascular (Potter, 1985; Grundemar & Ha˚kanson, 1990) and vascular studies . More recently, an involvement of postjunctional Y 2 receptors in vasoconstriction has also been suggested (Modin et al., 1991; McAuley & Westfall, 1992; Tessel et al., 1993; Lundberg & Modin, 1995; Nilsson et al., 1996; Malmstro¨m et al., 1998) . This has now been confirmed in vivo through the use of a selective Y 2 receptor antagonist, BIIE0246, in the pig spleen (Malmstro¨m, 2001 ) and kidney (Malmstro¨m et al., 2002) .
The importance of NPY on responses in the cutaneous microvasculature, relevant to the control of blood flow and inflammatory events, is unclear, especially the relative importance of the Y 1 and Y 2 receptors. Recently, the hormone PYY that is found predominantly in intestinal endocrine cells (Bo¨ttcher et al., 1984) has also been shown to be present in Langerhans cells (Lambert et al., 2002) , thus providing a local source of non-neuronal Y agonists. A constrictor effect of NPY has been demonstrated in human subcutaneous arteries (Morris, 1994; Nilsson et al., 1996) . Furthermore, NPY released from sympathetic nerves has been suggested to play a significant role in the regulation of the cutaneous microcirculation by sympathetic fibres under situations of high physiological activity, as determined by studies in the rat (Pinter et al., 1997) . This is of relevance to an observation that NPY acts to induce a vasodilatation as a consequence of stimulating presynaptic Y 2 receptors, inhibiting NA release and thus sympathetic tone (Hashim & Tadepalli, 1995) . The contribution of NPY to skin disease has been suggested (Wallengren, 1997) to be possibly related to the fact that NPY, in keeping with other peptides, possesses antimicrobial activity in the skin (Vouldoukis et al., 1996) . However, NPY, at high doses, has the ability to induce inflammation independently of Y receptors via activating mast cells (Shen et al., 1991) . More importantly, there is evidence, from a study involving Y 1 À/À receptor mice, that NPY plays a pivotal role in influencing pain processing and neurogenic oedema formation, through modulation of substance P released from sensory nerves (Naveilhan et al., 2001) . To build upon recent findings, we have used techniques designed to quantify events in the cutaneous microvasculature, in order to determine the contribution of Y 2 and Y 1 receptors to microvascular responses in the skin through the use of Y 2 À/À receptor mice and two competitive Y receptor antagonists (BIIE0246 and BIBO3304), which block Y 2 -and Y 1 agonist-induced responses, respectively.
Methods

Animals
Both male and female Y 2 þ / þ and Y 2 À/À receptor mice on a mixed C57BL/6-129/SvJ background between the ages of 8 -and 12 weeks were used in these studies (Sainsbury et al., 2002) . Animals were anaesthetised with urethane (25% w v À1 ; 2.5 g kg À1 i.p.) or isoflourane (3% delivered with O 2 , 5 : 95%).
99m Tc clearance assay as a measure of blood flow
Mice were anaesthetised with urethane (as above), the dorsal skin was shaved, and animals rested for 20 -30 min. Test agents were made up in Tyrode's solution (in mM: 137 NaCl, 2.7 KCl, 0.5 MgCl 2 , 0.4 NaH 2 PO 4 , 11.9 NaHCO 3 , 5.6 glucose), 99m Tc (0.04 -200 kBq) added, and kept on ice until use. Injection sites were marked out on the dorsal skin according to a randomised site pattern, and an aliquot of test agent (50 ml) was injected i.d., with an identical amount placed into a vial for measurement of the total radioactivity. A clearance period (30 min) was allowed before the animals were killed via anaesthetic overdose and cervical dislocation. The skin was removed and sites (8 mm diameter) punched out for measurement of the remaining radioactivity. Data were expressed as the change in % clearance compared to Tyrode-injected sites. Initially, the amount of 99m Tc cleared away from each site of injection was calculated, where % clearance was equal to counts measured in the injected skin divided by those in the same volume of uninjected test agent Â 100. From this, the clearance at test agent-injected sites was then compared to Tyrode (which was normalised to 100 for each experiment) for each test-injected site, and expressed as % change in clearance compared to Tyrode, with positive numbers indicating a decreased blood flow.
Extravascular accumulation of
125 I-BSA as a measure of oedema formation Animals were anaesthetised with urethane (as above), and plasma extravasation was measured as previously described (Cao et al., 1999 ) of test agents, a blood sample was obtained via cardiac puncture (0.5 ml), and centrifuged at 6000 Â g for 4 min to obtain a plasma sample. Animals were then killed via urethane overdose and cervical dislocation. The dorsal skin was removed, and the injected sites punched out. The amount of plasma extravasated (ml g À1 tissue) was calculated by comparing the amount of radioactivity in each skin site with that in 100 ml plasma from the same animal.
Myeloperoxidase assay as a measure of neutrophil accumulation
Animals were briefly anaesthetised with isoflurane and test agents were injected i.d. (50 ml site À1 ), as described above. After 4 h, the mice were humanely killed and skin sites (8 mm diameter) punched out and stored (À201C). Skin sites were homogenised in a phosphate buffer containing 0.5% hexadecyltrimethylammonium bromide detergent, and assayed for neutrophil numbers through measurement of myeloperoxidase (MPO) activity. The MPO assay was performed as previously (Cao et al., 2000) and as adapted from Schierwagen et al. (1990) , using the H 2 O 2 oxidation of 3,3 0 ,5,5 0 -tetramethyl benzidine. A mouse neutrophil standard obtained from peritoneal lavage samples following oyster glycogen injection (Moroney et al., 1988) was used to determine the number of neutrophils in samples. With the use of a microplate reader, optical density (OD) readings were taken at 620 nm every 5 min for 30 min, and a standard curve of OD was plotted against time. The number of neutrophils accumulating at the site of injection was calculated by comparison with mouse neutrophil standards, and expressed as neutrophil numbers ( Â 10 6 cells g À1 tissue).
Reagents
Agents were from Sigma, Poole, U.K., unless specified. NPY, the Y 1 -preferred agonist Pro
34
-NPY, the Y 2 -preferred agonist PYY(3-36) and human a/bCGRP were purchased from Bachem (Mersey side, England), and dissolved in distilled water. The stock solutions (10 nM) were stored at -201C and made up in Tyrode's solution just prior to use. (Wieland et al., 1998) 
were made up in DMSO (10%), and then diluted as required. They were given i.v. 5 min before i.d.-injected agents, and results were compared with the relevant vehicle control.
Statistical analysis
Results are presented as mean7s.e.m., unless otherwise indicated. Differences among data groups were calculated using the software program Prism (versions 3.03 and 4). Analyses were performed by one-way analysis of variance (ANOVA), followed by Bonferroni multiple comparison posttest, according to the selected pair of columns, or the twotailed paired and unpaired Student's t-tests where it is stated. The value of n quoted for experiments refers to the number of sites (animals) used, and these are stated in each figure. Po0.05 was considered as significant.
Results
Effect of NPY agonists on microvascular tone and permeability
The intradermal injection of NPY into the shaved dorsal skin induced a dose-dependent (30 -300 pmol) decrease in blood flow, as measured by the clearance of 99m Tc from the injected sites ( Figure 1a) , with a tendency for a lack of effect at the highest dose tested (1000 pmol). The Y 1 agonist Pro 34 -NPY (1 -1000 pmol; Figure 1b ) and the Y 2 -preferring agonist PYY(3 -36) (10 -1000; Figure 1c) Po0.001; ANOVA followed by Bonferroni's test) as compared to the basal response (Tyrode). In contrast, in the BIBO3304-pretreated group, only high doses of Pro 34 NPY (100 and 300 pmol) were able to produce a significant reduction in the blood flow as compared to Tyrode (Figure 2 ).
The effect of PYY(3 -36) on blood flow in age-matched Y 2 þ / þ and Y 2 À/À receptor mice is shown in Figure 3a . The decrease in blood flow induced by PYY(3 -36) was significantly attenuated in knockout mice, such that no significant change in blood flow was observed in this group as compared to Tyrode. In contrast, in the Y 2 þ / þ receptor animals, the PYY(3 -36)-induced decrease in blood flow was significantly different from Tyrode (10 and 100 pmol, 
Effect of NPY on microvascular permeability and neutrophil accumulation
The ability of the Y agonists to increase microvascular permeability, and thus to induce local oedema formation, was investigated at a range of doses. NPY was extremely weak at all doses (3 -1000 pmol) tested. Figure 5 shows the results from the substantial number of experiments performed for a 300 pmol dose of NPY, which had exhibited significant vasoconstrictor activity as described above. The previously published (Cao et al., 1999) activity of substance P (100 pmol) is also shown for comparison. NPY-induced oedema formation was also investigated in the presence of the vasodilator calcitonin gene-related peptide CGRP (Grant et al., 2002) to counteract the vasoconstrictor activity of NPY, but again a lack of oedema formation was observed. Furthermore, neither Y 1 nor Y 2 agonist was able to induce oedema formation ( Figure 5 ). 
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In a separate set of experiments, neutrophil accumulation, measured by the activation of neutrophil MPO, revealed that i.d. injection of NPY (300 pmol) did not produce neutrophil accumulation in the murine skin. However, the number of neutrophils extravasated in response to carrageenan (0.3 mg)-injected sites was significantly higher (Po0.001) than those observed in response to Tyrode or NPY (Figure 6 ).
Discussion
This study was carried out in order to investigate the possible involvement of Y 1 and Y 2 receptors in regulating microvascular responses in the skin by using techniques especially developed to allow quantification of blood flow, inflammatory oedema formation and polymorphonuclear leucocyte accumulation in the murine skin. Our data demonstrate that NPY acts to decrease blood flow in the murine cutaneous microvasculature, with a minor effect on the increased microvascular permeability that precedes oedema formation, and no effect upon leucocyte migration.
We have shown here for the first time that a 99m Tc clearance technique is also suitable to measure blood flow in the mouse skin, as it is in the rat skin (Chu et al., 2001) . The results reveal a small, but highly significant decrease in blood flow induced by NPY and both Y 1 -(Pro 34 NPY) and the Y 2 -(PYY(3 -36)) preferring receptor agonists. The absolute changes in 99m Tc clearance observed in the mice in response to these neuropeptides are of a similar magnitude to those observed with NA, but are smaller than those observed in response to vasoconstrictors in the rat skin (Chu et al., 2001 ). This might be related to the differences in the dorsal skin anatomy, which in rat is substantially thicker and thus more highly vascularised, allowing a greater difference to be observed in clearance between control and treated sites. Therefore, it is suggested that the small absolute size of the response is related to the extremely thin murine cutaneous layer, when compared with that in the rat.
The results, through the use of Pro 34 NPY, an agonist with preference for the Y 1 receptor, and at low concentrations, devoid of activity at the Y 2 receptor (Fuhlendorff et al., 1990) and the Y 1 antagonist BIBO3304, indicate a predominant role of the Y 1 receptor, as expected from previous studies in the skin and other tissues. One of the problems to date has been the lack of experimental tools to target possible Y 2 receptormediated responses. However, the Y 2 -preferring agonist PYY(3 -36) (Michel et al., 1998) has been shown to be of relevance to the skin, since PYY is present in Langerhans cells (Lambert et al., 2002) . In addition, mice lacking Y 2 À/À receptors are available, and have been shown to be insensitive to the anorectic effects of PYY(3 -36) (Batterham et al., 2002) . In the skin of Y 2 À/À mice, the decrease in blood flow in response to PYY(3 -36) was not significantly observed as compared to Tyrode, and not further blocked by the Y 1 receptor antagonist, thus providing evidence for a vasoactive contribution of the Y 2 receptor in murine skin. The selective Y 1 receptor antagonist BIBO3304 has subnanomolar affinity for the human and rat Y 1 receptors, with no affinity for the Y 2 receptor (Wieland et al., 1998) . BIBO3304 has been previously shown to antagonise NPYinduced blood pressure rises in the anaesthetised rat (Shin et al., 2000) . In this study, we have evidence for the first time that this compound also has a significant antagonistic effect in murine skin. The Y 2 antagonist BIIE0246 binds with low nanomolar affinity to the Y 2 receptor of species including human and rat, with no affinity for the Y 1 receptor (Doods et al., 1999; Dumont et al., 2000) . It blocks Y 2 receptormediated constriction of dog and rodent vessels in vitro (Dumont et al., 2000) , and selectively inhibits Y 2 receptormediated effects in isolated gastrointestinal tissues of human (Cox & Tough, 2002) and 129Sv mice and wild-type mice used in this study (Cox et al., 2001; Hyland et al., 2003) . Here we found that the Y 2 antagonist was only effective in mouse skin when the Y 1 antagonist was also present. We believe that this is evidence that the vasoconstriction induced by PYY(3 -36), included a Y 2 receptor-mediated component that is acting to facilitate the Y 1 receptor effects. It has been previously suggested that NPY may differently influence cutaneous microvascular events in the skin, in accordance with relative innervations at specific sites (Morris, 1999) , and this is highly relevant to this discussion.
Recent findings by Naveilhan et al. (2001) have indicated that NPY acts via the Y 1 receptor to mediate oedema formation in the mouse hind paw. Our data show that NPY and its analogues are extremely weak mediators of increased microvascular permeability, and thus the lack of oedema formation in the mouse dorsal skin was surprising since it disagrees with those by Naveilhan et al. (2001) , who suggested a role for NPY in stimulating sensory nerves and mediating pain and inflammation via the sensory neurogenic component (i.e. substance P). Interestingly, we, among others, have demonstrated the ability of substance P to mediate neurogenic oedema formation in the dorsal skin of mice, with a genetic background similar to that used in the present study (Cao et al., 1999) . The reasons for the difference in our results when compared with those of Naveilhan et al. (2001) are unknown. It should be noted, however, that their Y 2 À/À mice expressed part of the Y 2 receptor N-terminal together with the Neo gene, whose strong promoter activity could alter the function of nearby genes. In addition, we have investigated background differences, carrying out substantial experiments both in the mixed and single strain used in this study and in mice of the CD1 strain with no differences in phenotype (Brain et al., unpublished) .
In human tissues, RT -PCR and immunocytochemistry studies have been used to determine the distribution of the Y 1 and Y 2 receptors. Y 2 receptor mRNA was detected in trigeminal and superior cervical ganglia and in cerebral, menigeal and coronary blood vessels, and more weakly in subcutaneous arteries in the peripheral circulation (Uddman et al., 2002) , especially when compared with Y 1 receptor expression levels. Interestingly, evidence has been accumulating from studies by Zukowska-Grojec that the Y 2 receptor is important for angiogenesis of endothelial cells, as observed in an aortic sprouting assay (Zukowska-Grojec et al., 1998; Kitlinska et al., 2002) . The NPY-induced angiogenesis was impaired with ageing, and this was associated with a reduction in the expression of the Y 2 receptor, and of the enzyme that converts NPY to its biologically active product NPY(3 -36). In relation to our own results, it would be important that blood flow is controlled at sites of angiogenesis, and skin is a major site for angiogenesis associated with wound healing. This suggestion is supported by the very recent publication that demonstrated that the Y 2 receptor, but not the Y 1 , Y 4 or Y 5 receptors, were expressed in newly formed microvascular vessels in the mouse, and that wound healing is delayed in Y 2 À/À receptor mice (Ekstrand et al., 2003) . Furthermore, Lee et al. (2003) have recently supported the concept that the Y 2 receptor is mediating angiogenesis in the mouse, although they have also suggested a possible cooperative role for the Y 5 receptor. The use of Y 5 À/À receptor mice (Marsh et al., 1998) in future studies might be an attractive possibility to better characterise the role of Y 2 receptors in the changes in blood flow in the mouse microvasculature.
Thus, in conclusion, results using a combination of selective Y 1 and Y 2 antagonists and Y 2 À/À mice provide evidence that while the Y 1 receptor is predominant in mediating vasoconstriction in the cutaneous microvasculature, the Y 2 receptor also plays a modest but significant role. Our results demonstrate that NPY and selective agonists are weak in mediating oedema formation and neutrophil accumulation in the skin of this animal model. This leads us to suggest that NPY is unlikely to contribute to the oedema or cellular inflammatory component, while acting in a potent manner to modulate cutaneous blood flow.
